Identification

Summary

Tetradecyl hydrogen sulfate (ester) is an anionic surfactant used to treat small uncomplicated varicose veins.

Brand Names
Sotradecol
Generic Name
Tetradecyl hydrogen sulfate (ester)
DrugBank Accession Number
DB11328
Background

Sodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose veins 2.

Sodium tetradecyl sulfate has been widely used since the 1950s, and in 1978 the first successful report of injecting a 1% solution into spider angiomas in 144 patients was made. Also noted was an unspecified number of episodes of epidermal necrosis without significant long-term effects and a 30% incidence of post-sclerosis pigmentation that resolved within a few months 3.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 294.45
Monoisotopic: 294.18648062
Chemical Formula
C14H30O4S
Synonyms
  • 7-Ethyl-2-methyl-4-undecanol sulfate
  • Tetradecyl hydrogen sulfate

Pharmacology

Indication

Sotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small, uncomplicated varicose veins of the legs showing simple dilation, with competent valves 1.

Sodium tetradecyl sulfate has been designated as an orphan drug by the FDA for the treatment of gastrointestinal bleeding due to esophageal varices 8.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Telangiectasias or varicose veins occur in about 33% of adult women and about 15% of adult men. Sclerotherapy with sotradecol is widely used in the treatment of varicose veins 7.

Sotradecol (sodium tetradecyl sulfate injection) is a sclerosing agent. Intravenous (IV) injection of this agent causes blood vessel intima inflammation and thrombus formation. This normally occludes the injected vein, leading to a series of events. Subsequent formation of fibrous tissue results in partial or complete vein obliteration that may be temporary or permanent 1.

Mechanism of action

When injected directly into a vein, sodium tetradecyl sulfate causes intimal inflammation and venous thrombus formation, which then results in occlusion of the vein. Following this sequence of events, fibrous tissue forms and causes partial to complete obliteration of the vein, which may be temporary or permanent. An important role of this drug, as well as other sclerosing agents, is to control active hemorrhage and encourage hemostasis. This may be due to the esophageal and vascular smooth muscle spasm induced by the sclerosing agent 5.

During acute and active bleeding, the sodium tetradecyl sulfate injected directly into the esophageal varices may dissipate rapidly, as the varices have a much higher blood volume/flow rate and no functioning valves 5.

The mechanical compression effect of submucosal edema, created by the injection of sclerosing agents, may also be responsible for acute hemostasis 5.

TargetActionsOrganism
AEndothelial protein C receptor
antagonist
Humans
Absorption

Not Available

Volume of distribution

In humans, a large proportion (75%) of an injected dose of radiolabelled 3% sodium tetradecyl sulfate rapidly disappeared from the empty varicose vein injection site into communicating blood vessels with rapid entry into the deep veins of the calf 9.

In rats, at 72 hours after intravenous dosing of radiolabelled sodium tetradecyl sulfate, tissue levels of radiolabelled matter found in sample tissues (liver, kidney, lipid and skeletal muscle) were measured as very low. Although there was some evidence of radiolabel associated with the injection site, the levels were negligible 9.

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

After an intravenously administered radiolabelled dose, 70% of the drug was recovered in the urine of rats within 24 hours post-dosing 9.

At the end of the 72 hour post-dose period, 73.5% of the radiolabel had been recovered from the urine and 18.2% recovered from the faeces 9.

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

The intravenous LD50 of sodium tetradecyl sulfate in mice is 90 ± 5 mg/kg 1.

In the rat, the acute intravenous LD50 of sodium tetradecyl sulfate is estimated at 72 mg/kg and 108 mg/kg 1.

Adverse events are below:

Deep venous thrombosis

Because of the risk of deep vein thrombosis, patients must be evaluated for valvular competency and deep venous patency before treatment is initiated and slow injections of a small volume (< 2 mL) should be injected. It is recommended that patients be monitored post-treatment for both deep vein thrombosis and pulmonary embolism 12.

Air embolism

Stroke, transient ischemic attack, myocardial infarction, and impaired cardiac function have been associated with tetradecyl sulfate administration. Such sequelae may be caused by air embolism 5.

Local reaction

Local reactions including pain, itching or ulceration at the site of injection with permanent discoloration may remain along the path of the treated/sclerosed vein segment. Sloughing and/or necrosis of surrounding tissue may occur following extravasation from the injection site 1.

Allergic reactions

Hives, asthma, hay fever and anaphylactic shock have been reported with use of this drug 1.

*Mild systemic reactions *

Headache, nausea and vomiting 1.

Death A minimum of 6 deaths have reported with the use of Sotradecol. Four incidences of anaphylactic shock resulting in death have been reported in patients who received this drug 1.

One death has been reported in a patient who received Sotradecol while receiving an anti-ovulatory agent 1

Another death (from lethal pulmonary embolism) has been reported in a 36-year-old female treated with sodium tetradecyl acetate and was not taking oral contraceptive therapy 1

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
AcrivastineAcrivastine may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Adefovir dipivoxilAdefovir dipivoxil may decrease the excretion rate of Tetradecyl hydrogen sulfate (ester) which could result in a higher serum level.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Fibro-vein (Australasian Medical and Scientific Limited) / Fibro-Vein 3% (STD) / Fibrovein (Craveri) / Veinfibro (STD Pharmaceutical Products)
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
(sotradecol) Sodium Tetradecyl SulfateInjection, solution30 mg/1mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2021-06-25Not applicableUS flag
Sodium Tetradecyl SulfateInjection, solution10 mg/1mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2021-07-18Not applicableUS flag
SotradecolInjection, solution30 mg/1mLIntravenousAngiodynamics2004-12-012015-09-30US flag
SotradecolInjection, solution30 mg/1mLIntravenousMylan Institutional LLC2013-04-29Not applicableUS flag
SotradecolInjection, solution10 mg/1mLIntravenousAngiodynamics2004-12-012015-09-30US flag
SotradecolInjection, solution10 mg/1mLIntravenousA-S Medication Solutions2013-04-29Not applicableUS flag
SotradecolInjection, solution10 mg/1mLIntravenousMylan Institutional LLC2013-04-29Not applicableUS flag
SotradecolInjection, solution30 mg/1mLIntravenousA-S Medication Solutions2013-04-29Not applicableUS flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
6326W0DRHY
CAS number
300-52-7
InChI Key
GROJOWHVXQYQGN-UHFFFAOYSA-N
InChI
InChI=1S/C14H30O4S/c1-5-7-8-13(6-2)9-10-14(11-12(3)4)18-19(15,16)17/h12-14H,5-11H2,1-4H3,(H,15,16,17)
IUPAC Name
[(7-ethyl-2-methylundecan-4-yl)oxy]sulfonic acid
SMILES
CCCCC(CC)CCC(CC(C)C)OS(O)(=O)=O

References

General References
  1. SOTRADECOL- tetradecyl hydrogen sulfate (ester) injection, solution [Link]
  2. Sotradecol, PubChem [Link]
  3. Sodium tetradecyl sulfate [Link]
  4. Sodium Tetradecyl Sulfate [Link]
  5. PDR Sotradecol [Link]
  6. Evaluation of sodium tetradecyl sulfate and polidocanol as sclerosants for leg telangiectasia based on histological evaluation with clinical correlation [Link]
  7. Anaphylactoid Reaction After the Use of Sodium Tetradecyl Sulfate: A Case Report [Link]
  8. Drug Approval Package [Link]
  9. NZ Drug Safe Fibrovein [Link]
  10. Intralesional 3% Sodium Tetradecyl Sulfate for Treatment of Cutaneous Kaposi's Sarcoma [Link]
  11. Sodium tetradecyl sulfate actions [Link]
  12. Sotradecol [Link]
ChemSpider
8441
RxNav
1370424
ChEBI
75275
ChEMBL
CHEMBL1201345
MSDS
Download (253 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentVaricosities of the great saphenous vein1
4Unknown StatusTreatmentVenous Malformations1
4WithdrawnTreatmentSuperficial Venous Insufficiency, Varicose Veins1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntravenous10 mg/1mL
Injection, solutionIntravenous30 mg/1mL
Injection, solutionParenteral
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
PropertyValueSource
melting point (°C)199MSDS
Predicted Properties
PropertyValueSource
Water Solubility0.0104 mg/mLALOGPS
logP1.98ALOGPS
logP5.04ChemAxon
logS-4.4ALOGPS
pKa (Strongest Acidic)-1.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.6 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity77.77 m3·mol-1ChemAxon
Polarizability33.53 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor activity
Specific Function
Binds activated protein C. Enhances protein C activation by the thrombin-thrombomodulin complex; plays a role in the protein C pathway controlling blood coagulation.
Gene Name
PROCR
Uniprot ID
Q9UNN8
Uniprot Name
Endothelial protein C receptor
Molecular Weight
26671.245 Da
References
  1. Sodium tetradecyl sulfate actions [Link]

Drug created at December 03, 2015 16:52 / Updated at February 13, 2021 10:52